PROBLEM TO BE SOLVED: To provide new particular crystalline forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1- yl)-phenyl]-propionitrile, its hydrates and solvates, its salts and hydrates or solvates of its salts, which exhibit new physical properties for the dissolution of drug substances and/or facilitated routes of manufacturing/purification.SOLUTION: This invention relates to: crystal forms of monohydrate of a compound, crystal forms of monotosylate monohydrate, crystal forms of monotosylate dihydrate, crystal forms of ditosylate, and the like； method of manufacturing them； and pharmaceutical composition containing them.【課題】薬物の溶解および／または製造／精製の容易な経路のための新規物理特性を示す２－メチル－２－［４－（３－メチル－２－オキソ－８－キノリン－３－イル－２，３－ジヒドロ－イミダゾ［４，５－ｃ］キノリン－１－イル）－フェニル］－プロピオニトリル、その水和物および溶媒和物、その塩ならびにその塩の水和物もしくは溶媒和物の特定の新規結晶形態の提供。【解決手段】前記化合物の一水和物の結晶形態、一トシル酸塩一水和物の結晶形態、一トシル酸塩二水和物の結晶形態、二トシル酸塩の結晶形態などの結晶形態、、これらの製造法、これらを含む医薬組成物。【選択図】なし
